Oral Food Challenge for FPIES in Practice-A Survey: Report from the Work Group on FPIES Within the Adverse Reactions to Foods Committee, FAED IS, AAAAI.

Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy diagnosed via history and/or an oral food challenge (OFC).

Objective: To determine allergists' approach to FPIES OFCs.

Methods: A web-based survey was e-mailed to 1100 randomly selected American Academy of Allergy, Asthma and Immunology members.

Disseminated Infection in an Adolescent With a Mutation.

An adolescent with failure to thrive developed cuboid bone osteomyelitis and brain abscesses. Mold isolated from both locations was identified by universal genetic sequencing as spp, which is typically a pathogen of reptiles. The patient was subsequently diagnosed with a mutation and was successfully treated.

Food Allergy Immunotherapy with Adjuvants.

Treatment of immunoglobulin E-mediated food allergy has traditionally been limited to allergen avoidance and emergency treatment after accidental ingestion. In recent years, significant progress has been made with oral, sublingual, and epicutaneous immunotherapy in the treatment of food allergy; however, these emerging treatment options have important limitations in efficacy, durability of effect, and safety. These limitations have already spurred interest in the development of adjuvant therapies to increase efficacy, produce more durable immunologic changes, and/or reduce treatment-related adverse reactions.

Inherited and acquired clinical phenotypes associated with neuroendocrine tumors.

Purpose Of Review: Overview of neuroendocrine neoplasms in the context of their associations with primary and secondary immunodeficiency states.

Recent Findings: Malignancies of neuroendocrine origin are well known to be associated with hereditary syndromes, including multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome, neurofibromatosis type 1, and tuberous sclerosis. This review includes the X-linked form of hyper-IgM syndrome (XHIGM), due to mutations in the CD40Ligand gene (CD40LG), as an additional inherited disorder with susceptibility to such malignancies, and discusses neuroendocrine tumors (NETs) arising in other immunocompromised states.